Cellebrite DI (NASDAQ:CLBT) CRO Sells $161,642.66 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Marcus Jewell also recently made the following trade(s):

• On Tuesday, May 12th, Marcus Jewell sold 383 shares of Cellebrite DI stock. The stock was sold at an average price of $13.01, for a total transaction of $4,982.83.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $13.17 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98. The company’s fifty day simple moving average is $13.41 and its 200-day simple moving average is $15.40. The stock has a market capitalization of $3.29 billion, a PE ratio of 47.04, a P/E/G ratio of 1.60 and a beta of 1.15.

Institutional Investors Weigh In On Cellebrite DI

Institutional investors have recently bought and sold shares of the business. CWM LLC lifted its position in shares of Cellebrite DI by 85.7% in the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares in the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI during the third quarter worth about $40,000. First Horizon Corp raised its stake in Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after purchasing an additional 2,337 shares during the period. Finally, Vestcor Inc purchased a new position in Cellebrite DI in the 3rd quarter worth approximately $70,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CLBT. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Needham & Company LLC reduced their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.